Janssen Cilag Ltd

Lobbying Organisation Janssen Cilag Ltd

Date published 25 May, 2018

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 Jan, 2018 to 30 Apr, 2018

Specific Details The 2016 Framework Agreement on the Pricing and Supply of Medicines

Intended results To update on the delays in the reimbursement of new medicines and ensure that Ireland is as fast as other EU countries in granting patients access.

Name of person primarily responsible for lobbying on this activity Anna Rafferty

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Meeting which took place in Leinster house was to discuss the current delays being experienced by the Pharmaceutical Industry in relation to the reimbursement of new medicines. The savings being delivered by the current agreement were discussed. An outline was provided on how Ireland is ranked 16th out of 26th in the EU in approving new medicines. The importance of a transparent and predictable reimbursement process was outlined.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Catherine Byrne TD (Dáil Éireann, the Oireachtas)